资料显示，公司主营类生物制品。 报告期内，公司核心产品特瑞普利单抗注射液（商品名：拓益®）于国内市场销售收入同比大幅增长约 37.72%。截至本公告披露日，拓益®已在中国内地获 批上市的 12 项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗 PD-1 单抗药物。 公司亦持续拓展全球商业化网络，截至本公告披露日，特瑞普利单抗已在中国内地、中国香港、美国、欧盟、印度、英国、澳大利亚和新加坡等40 多个国 家和地区获批上市，并在全球多个国家和地区接受上市审评。 中证智能财讯君实生物（688180）2月27日晚间披露2025年业绩快报，公司实现营业收入24.98亿元，同比增长28.23%；归母净利润亏损8.74亿元，上年同期 亏损12.81亿元；扣非净利润亏损9.89亿元，上年同期亏损12.9亿元；基本每股收益-0.87元，加权平均净资产收益率为-14.7%。以最新收盘价计算，市净率 （LF）约5.62倍，市销率（TTM）约14.06倍。 以本次披露业绩快报数据计算，公司近年市盈率（TTM）图如下所示： 市净率=总市值/净资产。市净率估值法多用于盈利波动较大而净资产相对稳定的公司。 ...

Investment Rating - The report assigns an "Accumulate-A" investment rating with a target price of 11.13 yuan over the next six months [5][6][10]. Core Insights - The company reported a revenue of 674 million yuan for the first half of 2025, a decrease of 11.24% year-on-year, while the net profit attributable to shareholders was 51 million yuan, down 35.37% year-on-year [1]. - In Q2 2025, the company achieved a revenue of 242 million yuan, marking a year-on-year growth of 3.86%, with a net profit of -17 million yuan, an improvement from -29 million yuan in the same period last year [1][2]. - The company maintains a stable core competency in brewing technology and focuses on innovation, successfully launching new products that have received positive market feedback [2][4]. Financial Performance - For Q2 2025, the gross margin was 54.96%, an increase of 3.58 percentage points year-on-year, while the net margin improved with a decrease of 5.31 percentage points year-on-year [3]. - The sales expense ratio and management expense ratio were 33.88% and 14.88%, respectively, showing a year-on-year decrease of 1.63 percentage points and 5.34 percentage points [3]. Market Position and Strategy - The company is committed to long-term strategies, focusing on the local banquet market in Qinghai and actively developing county-level markets while accelerating national product layout [4]. - The company aims to enhance its market share in the province and expand into surrounding markets, positioning itself to seize future industry opportunities [4].